Legal & General Group PLC Regenxbio Inc. Transaction History

Legal & General Group PLC

  • $357 Billion
  • Q1 2025

A detailed history of Legal & General Group PLC transactions in Regenxbio Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 8,790 shares of RGNX stock, worth $86,054. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,790
Previous 44,823 80.39%
Holding current value
$86,054
Previous $346,000 82.08%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025
SELL
$5.92 - $8.7 $213,315 - $313,487
-36,033 Reduced 80.39%
8,790 $62,000
Q4 2024

Feb 13, 2025
SELL
$7.23 - $11.56 $555,213 - $887,727
-76,793 Reduced 63.14%
44,823 $346,000
Q3 2024

Feb 28, 2025
BUY
$10.49 - $14.39 $764,773 - $1.05 Million
72,905 Added 162.65%
117,728 $1.23 Million
Q3 2024

Nov 14, 2024
BUY
$10.49 - $14.39 $1,552 - $2,129
148 Added 0.12%
121,616 $1.28 Million
Q2 2024

Aug 14, 2024
BUY
$11.51 - $21.53 $110,818 - $207,290
9,628 Added 8.61%
121,468 $1.42 Million
Q1 2024

May 14, 2024
BUY
$12.17 - $24.61 $20,226 - $40,901
1,662 Added 1.51%
111,840 $2.36 Million
Q4 2023

Feb 15, 2024
BUY
$12.89 - $20.82 $1,598 - $2,581
124 Added 0.11%
110,178 $1.98 Million
Q3 2023

Nov 14, 2023
BUY
$16.46 - $19.99 $21,809 - $26,486
1,325 Added 1.22%
110,054 $1.81 Million
Q2 2023

Aug 14, 2023
SELL
$17.23 - $21.71 $56,307 - $70,948
-3,268 Reduced 2.92%
108,729 $2.17 Million
Q1 2023

May 15, 2023
SELL
$18.08 - $24.55 $20,358 - $27,643
-1,126 Reduced 1.0%
111,997 $2.12 Million
Q4 2022

Feb 14, 2023
BUY
$20.4 - $24.73 $55,487 - $67,265
2,720 Added 2.46%
113,123 $2.57 Million
Q3 2022

Nov 14, 2022
BUY
$22.29 - $35.04 $45,605 - $71,691
2,046 Added 1.89%
110,403 $2.92 Million
Q2 2022

Aug 22, 2022
SELL
$19.35 - $35.04 $2,844 - $5,150
-147 Reduced 0.14%
108,357 $2.68 Million
Q1 2022

May 16, 2022
SELL
$24.62 - $34.31 $11,079 - $15,439
-450 Reduced 0.41%
108,504 $3.6 Million
Q4 2021

Feb 14, 2022
BUY
$30.19 - $40.28 $106,570 - $142,188
3,530 Added 3.35%
108,954 $3.56 Million
Q3 2021

Nov 15, 2021
BUY
$29.09 - $45.68 $333,051 - $522,990
11,449 Added 12.18%
105,424 $4.42 Million
Q2 2021

Aug 12, 2021
SELL
$32.46 - $40.48 $734,180 - $915,576
-22,618 Reduced 19.4%
93,975 $3.65 Million
Q1 2021

May 17, 2021
BUY
$33.61 - $49.95 $587,536 - $873,175
17,481 Added 17.64%
116,593 $3.98 Million
Q4 2020

Feb 12, 2021
BUY
$26.52 - $49.35 $10,395 - $19,345
392 Added 0.4%
99,112 $4.5 Million
Q3 2020

Nov 13, 2020
SELL
$27.01 - $40.26 $126,974 - $189,262
-4,701 Reduced 4.55%
98,720 $2.72 Million
Q2 2020

Aug 14, 2020
BUY
$27.75 - $43.44 $199,827 - $312,811
7,201 Added 7.48%
103,421 $3.81 Million
Q1 2020

May 14, 2020
BUY
$21.5 - $54.2 $13,609 - $34,308
633 Added 0.66%
96,220 $3.12 Million
Q4 2019

Feb 13, 2020
BUY
$34.54 - $44.87 $353,620 - $459,379
10,238 Added 12.0%
95,587 $3.92 Million
Q3 2019

Nov 13, 2019
BUY
$31.84 - $50.88 $121,947 - $194,870
3,830 Added 4.7%
85,349 $3.04 Million
Q2 2019

Aug 14, 2019
BUY
$42.0 - $59.29 $18,228 - $25,731
434 Added 0.54%
81,519 $4.19 Million
Q1 2019

May 15, 2019
BUY
$40.82 - $62.45 $312,803 - $478,554
7,663 Added 10.44%
81,085 $4.65 Million
Q4 2018

Feb 15, 2019
BUY
$39.11 - $75.15 $137,432 - $264,077
3,514 Added 5.03%
73,422 $3.07 Million
Q3 2018

Nov 20, 2018
BUY
$65.0 - $82.15 $1.07 Million - $1.36 Million
16,522 Added 30.95%
69,908 $5.28 Million
Q2 2018

Aug 10, 2018
BUY
$27.2 - $74.35 $1.31 Million - $3.58 Million
48,150 Added 919.6%
53,386 $3.83 Million
Q1 2018

May 17, 2018
SELL
$24.05 - $37.5 $39,201 - $61,125
-1,630 Reduced 23.74%
5,236 $156,000
Q4 2017

Feb 13, 2018
BUY
$26.0 - $34.6 $178,516 - $237,563
6,866
6,866 $229,000

Others Institutions Holding RGNX

# of Institutions
181
Shares Held
45.3M
Call Options Held
64.9K
Put Options Held
103K
View Full List

About REGENXBIO Inc.

RGNX Quotes by TradingView
  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $423M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email